Abstract
Therapeutic management and research in Amyotrophic Laterals Sclerosis (ALS) have been limited by the substantial heterogeneity in progression and anatomical spread that are endemic of the disease. Neuroimaging biomarkers represent powerful additions to the current monitoring repertoire but have yielded inconsistent associations with clinical scores like the ALS functional rating scale. The D50 disease progression model was developed to address limitations with clinical indices and the difficulty obtaining longitudinal data in ALS. It yields overall disease aggressiveness as time taken to reach halved functionality (D50); individual disease covered in distinct phases; and calculated functional state and calculated functional loss as acute descriptors of local disease activity. It greatly reduces the noise of the ALS functional rating scale and allows the comparison of highly heterogeneous disease and progression subtypes. In this study, we performed Voxel-Based Morphometry for 85 patients with ALS (60.1±11.5 years, 36 female) and 62 healthy controls. Group-wise comparisons were performed separately for gray matter and white matter using ANCOVA testing with threshold-free cluster enhancement. ALS-related widespread gray and white matter density decreases were observed in the bilateral frontal and temporal lobes (p<0.001, family-wise error corrected). We observed a progressive spread of structural alterations along the D50-derived phases, that were primarily located in frontal, temporal and occipital gray matter areas, as well as in supratentorial neuronal projections (p<0.001 family-wise error corrected). ALS patients with higher overall disease aggressiveness (D50 < 30 months) showed a distinct pattern of supratentorial white matter density decreases relative to patients with lower aggressiveness; no significant differences were observed for gray matter density (p<0.001 family-wise error corrected). The application of the D50 disease progression model separates measures of disease aggressiveness from disease accumulation. It revealed a strong correlation between disease phases and in-vivo measures of cerebral structural integrity. This study underscores the proposed corticofugal spread of cerebral pathology in ALS. We recommend application of the D50 model in studies linking clinical data with neuroimaging correlates.
Highlights
Amyotrophic lateral sclerosis (ALS) is a progressive multi-systemic neurodegenerative disorder, with most patients typically succumbing to respiratory failure 2–5 years from symptom onset (Dorst et al, 2018; Kiernan et al, 2011)
Additional decreases in White Matter (WM) density were observed in the bilateral temporal lobes, but not within cerebellar projections (FWE-corrected p < 0.001, Fig. 2, Supplementary Table 2A)
Sub-group comparisons showed that in contrast to patients with limb-onset, bulbar–onset patients presented with significantly decreased bifrontal and bitemporal Gray Matter (GM) and WM density (FWE-corrected p < 0.001, Supplementary Fig.1)
Summary
Amyotrophic lateral sclerosis (ALS) is a progressive multi-systemic neurodegenerative disorder, with most patients typically succumbing to respiratory failure 2–5 years from symptom onset (Dorst et al, 2018; Kiernan et al, 2011). Both ALS research and care are severely constrained by substantial intra- and inter-individual phenotypic heterogeneity and the lack of well-characterized and large longitudinal data sets. Voxel-Based Morphometry (VBM) in particular has already demonstrated group-wise regional differences in cerebral tissue compartments of T1 images (Ashburner and Friston, 2000).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have